1. Generics Bulletin
  2. >>Business
  3. >>Earnings

Euroapi Shares Nosedive As It Takes Axe To 2023 Guidance Late In The Year

18-Month Old Firm Sees Customer Destocking For APIs, Biotech ‘Funding Crisis’

 
• By Dean Rudge

Investors voted with their feet after Sanofi’s spunoff standalone API manufacturing and CDMO business announced a radical downshift in expectations for 2023, while pausing longer term targets.

Vintage inscription made by old typewriter, warning
• Source: Shutterstock

Euroapi, Sanofi-spunoff standalone active pharmaceutical ingredient manufacturing business, has heavily rowed back its financial expectations for 2023 and hit pause on its longer-term targets, citing several external challenges as it announced plans to launch a fresh strategic review to adapt to the new environment it sees.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

Despite Multiple Headwinds, Formycon Remains Positive For Its Biosimilars Growth

 
• By Urtė Fultinavičiūtė

Partnering opportunities, paused marketing, approvals, litigations, and many more. Formycon sets out the agenda for 2025, after seeing a bumpy start to the year.

Teva Crib Sheet Reveals Uzedy, Lenalidomide Expectations Ahead Of Q1

 
• By Dean Rudge

Teva is charting a new course under its ‘Pivot to Growth’ strategy, providing a memory aid for investors to better understand the firm’s financials going into 2025.

Alvotech Reveals Ramp-Up In Development As Sales Explode In 2024

 
• By Dave Wallace

With sales and profits shooting up in 2024, Alvotech has revealed plans to rapidly accelerate development to add between four and six programs to its pipeline of biosimilars every year, while at the same time unveiling details of several new brands that it will be seeking to challenge. The firm has also set out longer-term financial targets that anticipate more than trebling its revenues in the next three years.

Henlius Builds Profitability Streak With Second Year In The Black

 
• By Adam Zamecnik

The Chinese player reported its second profitable year in a row, with growth in sales reported across its marketed portfolio and further milestones in the near future.

More from Business

Despite Multiple Headwinds, Formycon Remains Positive For Its Biosimilars Growth

 
• By Urtė Fultinavičiūtė

Partnering opportunities, paused marketing, approvals, litigations, and many more. Formycon sets out the agenda for 2025, after seeing a bumpy start to the year.

Celltrion Unveils Strategy Amid Series Of Milestones

 
• By Adam Zamecnik

South Korea’s Celltrion has doubled down on its efforts in further building its pipeline, eyeing a target of 22 commercialized products by 2030 while also aiming to submit INDs for 13 novel compounds.

Samsung Rolls Out Second US Soliris Biosimilar – At 30% WAC Discount

 
• By Dean Rudge

Samsung Bioepis and Teva have provided clarity on the pricing of their Epysqli biosimilar to Soliris in the US, as the firms launched only the second rival to the rare diseases treatment.